Phase 1 Data for CITY-FXI, an RNAi Therapeutic Candidate for Thromboembolic Diseases, Selected for Oral Presentation at the 68th ASH Annual Meeting
City Therapeutics' Phase 1 data for CITY-FXI, an RNAi candidate targeting Factor XI for thromboembolic diseases, was selected for an oral presentation at the 68th ASH Annual Meeting on December 12, 2026. The oral session will cover single-ascending dose results in healthy volunteers plus initial data from patients with Factor V Leiden or prothrombin G20210A mutation; CITY-TFR2 preclinical data will appear as a poster.
Key figures
- Drug Name
- CITY-FXI
- Phase Of Trial
- Phase 1
- Conference
- 68th ASH Annual Meeting, December 12-15, 2026, New Orleans
- Abstract Numbers
- ["189","1122"]
- Presentation Format
- oral (CITY-FXI), poster (CITY-TFR2)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.